Education
About Us
Working with TipRanks
Follow Us
Immunocore Holdings (IMCR)
NASDAQ:IMCR
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.2Last Year’s EPS
-0.23Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: 17.28%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a strong performance in revenue growth and global expansion of KymTrak, as well as promising advancements in clinical trials and a solid financial position. However, challenges in European reimbursement and uncertainties in HIV treatment results were noted. The overall sentiment is predominantly positive due to significant achievements outweighing the challenges.Company Guidance
During the Immunocore Holdings plc conference call for the fourth quarter and full year 2024, the company provided various metrics highlighting its performance and future guidance. KymTrak, a key product, generated $310 million in net revenues for the year, reflecting a 30% year-on-year growth, with $84.1 million in net revenues in Q4, marking a 5% increase from the prior quarter. The U.S. market saw significant growth, contributing $206 million, a 34% increase year-on-year. Immunocore's clinical pipeline progressed with three ongoing phase three trials, including TEBIAM and ATOM for melanoma, and the initiation of two phase one trials. The company also advanced into autoimmune diseases, targeting type 1 diabetes and atopic dermatitis. For 2025, Immunocore expects incremental growth in KymTrak led by U.S. market penetration and new international launches, with R&D expenses projected to increase as they advance their pipeline. Immunocore reported a strong cash position of $820 million, supporting its continued focus on delivering transformative medicines.KymTrak Revenue Growth
KymTrak achieved a 5% growth in Q4 versus Q3, with a 30% year-on-year revenue growth, culminating in a total of $310 million in revenue for the year 2024.
Global Expansion of KymTrak
KymTrak was launched in fourteen new countries, bringing the total to thirty-nine countries. It has over 80% market share of HLA-201 positive patients in major markets.
Strong Financial Position
Immunocore Holdings reported $820 million in cash and marketable securities at the end of 2024 after repaying a $50 million loan.
Advancement of Clinical Trials
Progress was made in three ongoing phase three trials, including TEBIAM and ATOM, and a new trial, Plizumel, was initiated. Two phase one trials with novel molecules were also started.
Promising Pipeline in Infectious Diseases and Autoimmune
Completion of the HBV single ascending dose trial and progress in HIV trials, with advancements in autoimmune candidates targeting type 1 diabetes and atopic dermatitis.
IMCR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IMCR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | $28.06 | $29.92 | +6.63% |
Feb 26, 2025 | $29.21 | $30.77 | +5.34% |
Nov 06, 2024 | $32.99 | $33.51 | +1.58% |
Aug 08, 2024 | $36.90 | $37.92 | +2.76% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Immunocore Holdings (IMCR) report earnings?
Immunocore Holdings (IMCR) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is Immunocore Holdings (IMCR) earnings time?
Immunocore Holdings (IMCR) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IMCR EPS forecast?
IMCR EPS forecast for the fiscal quarter 2025 (Q2) is -0.2.